Harrow, Inc. $HROW Shares Sold by Royce & Associates LP

Royce & Associates LP lessened its stake in Harrow, Inc. (NASDAQ:HROW) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 509,746 shares of the company’s stock after selling 23,267 shares during the period. Royce & Associates LP owned 1.38% of Harrow worth $24,978,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the stock. 12th Street Asset Management Company LLC acquired a new position in Harrow in the fourth quarter valued at $4,465,000. Larson Financial Group LLC boosted its stake in shares of Harrow by 13.1% during the fourth quarter. Larson Financial Group LLC now owns 2,446 shares of the company’s stock worth $120,000 after buying an additional 284 shares during the period. ProShare Advisors LLC boosted its stake in shares of Harrow by 10.3% during the fourth quarter. ProShare Advisors LLC now owns 7,406 shares of the company’s stock worth $363,000 after buying an additional 693 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in shares of Harrow by 73.1% during the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 9,000 shares of the company’s stock worth $441,000 after buying an additional 3,800 shares during the period. Finally, Blackhawk Capital Partners LLC boosted its stake in shares of Harrow by 23.2% during the fourth quarter. Blackhawk Capital Partners LLC now owns 134,758 shares of the company’s stock worth $6,603,000 after buying an additional 25,337 shares during the period. Institutional investors and hedge funds own 72.76% of the company’s stock.

Insider Transactions at Harrow

In related news, CFO Andrew R. Boll bought 3,500 shares of the company’s stock in a transaction on Thursday, May 14th. The stock was bought at an average cost of $29.90 per share, with a total value of $104,650.00. Following the completion of the acquisition, the chief financial officer owned 814,679 shares in the company, valued at approximately $24,358,902.10. This represents a 0.43% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Adrienne L. Graves bought 1,000 shares of the company’s stock in a transaction on Monday, May 18th. The stock was bought at an average cost of $31.07 per share, with a total value of $31,070.00. Following the completion of the acquisition, the director owned 1,000 shares of the company’s stock, valued at $31,070. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 12.80% of the company’s stock.

Harrow Price Performance

Shares of NASDAQ:HROW opened at $34.17 on Wednesday. The company has a quick ratio of 2.30, a current ratio of 2.48 and a debt-to-equity ratio of 10.30. The company has a market cap of $1.27 billion, a P/E ratio of -83.34 and a beta of 0.34. Harrow, Inc. has a 52 week low of $25.53 and a 52 week high of $54.85. The company has a 50-day moving average price of $36.02 and a 200 day moving average price of $41.94.

Harrow (NASDAQ:HROW) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.31). The firm had revenue of $44.20 million during the quarter, compared to analyst estimates of $52.43 million. Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. During the same quarter in the previous year, the business earned ($0.38) EPS. Research analysts predict that Harrow, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on HROW. Weiss Ratings downgraded shares of Harrow from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. B. Riley Financial reiterated a “buy” rating and set a $65.00 target price (down from $74.00) on shares of Harrow in a research note on Tuesday, April 7th. Zacks Research upgraded shares of Harrow from a “strong sell” rating to a “hold” rating in a research note on Friday, April 3rd. William Blair reiterated an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Finally, BTIG Research reiterated a “buy” rating and set a $63.00 target price on shares of Harrow in a research note on Tuesday, May 12th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $69.43.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.